Navigation Links
Frost & Sullivan Lauds SnooZeal's Unique Electrical Stimulation Therapy for Sleep Apnea in the European Market
Date:2/22/2017

LONDON, Feb. 22, 2017 /PRNewswire/ -- Based on its recent analysis of the sleep apnea therapy market, Frost & Sullivan recognizes SnooZeal, Inc. with the 2017 European New Product Innovation Award. SnooZeal is a highly innovative product that intelligently addresses the root causes of sleep apnea by training the tongue muscles through the clinically proven continuous transmucosal electrical stimulation therapy. Because of its over-the-counter (OTC) status, SnooZeal is one of the most accessible anti-snoring products available in the market today. This ease of access has enabled the company to build a clear competitive advantage in terms of early market access.

Unlike competitive anti-snoring therapies widely prescribed as viable treatment options for sleep apnea patients, SnooZeal's product is based on the simple principle of electrically stimulating the tongue muscles in a non-invasive manner to exercise the over-relaxed muscles. SnooZeal is the only product in the European market used as a therapy during waking hours, enhancing patient convenience and adherence. To be cured of various stages of sleep apnea, the user needs to wear the mouthpiece for at least 20 minutes twice a day for a minimum of 6 weeks.

Continue Reading
SnooZeal Receives 2017 European Sleep Apnea Therapies New Product Innovation Award
SnooZeal Receives 2017 European Sleep Apnea Therapies New Product Innovation Award

"The device is designed to accommodate the treatment needs of patients suffering from various degrees of sleep-disordered breathing by optimizing treatment parameters, which are clinically demonstrated to deliver best results and autonomy to patients," said Frost & Sullivan Industry Analyst Arjunvasan Ambigapathy. "SnooZeal anti-snoring therapy helps patients consciously correct their symptoms, which is clinically demonstrated to be more effective than therapies that are administered when the patient is unconscious. SnooZeal is the only therapeutic option aimed at reversing the cause of this condition, a value that is not seen in most widely-prescribed products in the market today."

One of SnooZeal's most innovative features is its simple design comprising three components:

  • a wearable mouthpiece in the form of a glove that fits onto the tongue
  • a rechargeable control unit attached to the mouthpiece through a mini-USB connection
  • a remote control unit and a smartphone app to manage various treatment parameters that are ideal for patients

When designing the mouthpiece, SnooZeal's team worked with various dentists and maxillofacial surgeons to ensure the product is flexible enough to cover and fit various tongue sizes, without restricting its potential for OTC sales across specific geographies. The product's ease of use; enhanced mobile connectivity; and better collaboration with care providers before, during, and after the therapy have made SnooZeal a truly user-friendly, innovative medical device.

Within a year of its inception, SnooZeal received commercial approval from European healthcare authorities to offer its product OTC as a clinically safe and effective alternative to sleep apnea therapy. The product is awaiting approval from the Food and Drug Administration (FDA) and will soon be available in the United States, which had subsequently garnered the attention of leading investors.

"Being CE-approved for sale in the European market, SnooZeal aims to present its products across both retail and online channels in the United Kingdom, Germany, Switzerland, France, and other major European economies in the near future," noted Arjunvasan Ambigapathy. "With plans to expand its market across emerging economies such as Russia, Mexico, India, China, Canada, and Brazil, SnooZeal's net market value could be higher than most medical device companies in this emerging industry sector and most other companies operating within the European market today."

For successfully meeting the core customer requirements of quality, functionality, clinical effectiveness, and reliability, SnooZeal's sleep apnea product richly deserves Frost & Sullivan's honour.

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the product's value-added features/benefits and the increased return on investment (ROI) it offers customers, which in turn raise customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About SnooZeal, Inc.

SnooZeal's antisnoring and sleep apnea device scored a CE mark, making it the first commercially available over-the-counter device that targets the underlying cause of snoring.

The SnooZeal device addresses the excessive relaxation and loss of tongue muscle tone during sleep. The device is worn for 20 to 25 minutes twice a day over six weeks. It delivers electric pulses to the back of the tongue to increase muscle tone with the goal of reversing the over-relaxation of the tongue during sleep. The patient uses a smartphone app to control the treatment.
The daytime treatment differentiates SnooZeal from currently available treatments that are used at night.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that could make or break today's market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the Discussion.

Contact:

Chiara Carella
P: +44 (0) 207.343.8314
F: 210.348.1003
E: chiara.carella@frost.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/frost--sullivan-lauds-snoozeals-unique-electrical-stimulation-therapy-for-sleep-apnea-in-the-european-market-300411214.html


'/>"/>
SOURCE Frost & Sullivan
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets
2. Mega Trends Foster Investment, Innovation and Expansion in Latin America, Finds Frost & Sullivan
3. Frost & Sullivan Market Share Leadership Award Highlights Acuo Technologies Accomplishments in Enterprise Imaging Informatics
4. Development of New Technologies Spurs Molecular Diagnostic Test Volumes in Asia-Pacific, Finds Frost & Sullivan
5. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Global In Vitro Diagnostics Markets Outpace Pharma Industry Growth, finds Frost & Sullivan
8. Frost & Sullivan: Standardized Regulations Crucial for Growth in Global Dimensional Metrology Market for Medical Devices
9. Frost & Sullivan: mHealth Serves as the Catalyst for Healthcares Evolution
10. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
11. Frost & Sullivan: Expiration of Patents for Leading Drugs to Bolster the Oral Solid Drug Dosage Excipients Market in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... 17, 2019 , ... Argos Risk, an industry leader of ... sector during the second quarter of 2019. Three nationwide companies, whose primary focus ... strong client list in managing and mitigating third-party risk. , “We are excited ...
(Date:7/17/2019)... ... July 17, 2019 , ... For the second year in a row, Astro Pak is honored ... by the Orange County Business Journal, which is the second largest business journal in California. ... with the additional honor of ranking third place in the medium size employer category. For ...
(Date:7/13/2019)... ... 2019 , ... Meet the Pettys, Will and Jamie Petty met in 2011 and soon became ... LDS Temple just six months later. , For the next three years Will and Jamie ... their family. In 2015 the decision was made to begin the process of trying. After ...
Breaking Medicine Technology:
(Date:7/13/2019)... ... July 12, 2019 , ... ... Clark County. The office is located at 5380 S. Rainbow Blvd., Suite 210, ... Center. , The cancer center is equipped with state-of-the-art medical equipment plus all ...
(Date:7/13/2019)... CHARLOTTE, N.C. (PRWEB) , ... July 12, 2019 ... ... brand (NYSE American: YCBD), has been named a “Brand to Watch” by Brightfield ... Brightfield Group ranked cbdMD in the top 10 of domestic CBD companies in ...
(Date:7/13/2019)... ... July 12, 2019 , ... The American Med Spa Association (AmSpa) has released ... help medical aesthetic and medical spa professionals understand the realities of the industry and ... “It’s been two years since AmSpa released the 2017 Medical Spa State of the ...
(Date:7/12/2019)... ... ... Rebecca Baxt, M.D., F.A.A.D. and Saida Baxt, M.D., F.A.A.D. of BAXT CosMedical ... BAXT CosMedical is a renowned facility that believes in honest consultations and natural results ... years. , NJ Top Docs, Dr. Rebecca Baxt and Dr. Saida Baxt pride themselves ...
(Date:7/11/2019)... (PRWEB) , ... July 11, 2019 , ... ... new knowledge tools and educational resources with a range of features to further ... across the global pharmaceutical industry in manufacturing quality medicines for patients worldwide. The ...
Breaking Medicine News(10 mins):